- Gene-editing technology may help scientists discern whether genetic variations with undetermined effects are harmless or dangerous.
- Researchers used the technology to assess a genetic variant suspected to have a role in enlarged hearts.
- Gene editing may help assess a person’s individual disease risk and improve the quality and predictive abilities of precision medicine.
Embargoed until 4 a.m. CT / 5 a.m. ET Monday, June 18, 2018
DALLAS, July 18, 2018 — Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies, according to new research in the American Heart Association’s journal Circulation.
For the first time, the study demonstrates the unique potential of combining stem cell-based disease modeling (Induced pluripotent stem cells) and CRISPR/Cas9-mediated genome editing technology as a personalized risk-assessment platform for determining the disease-causing ability of a yet undescribed genetic variant, known as a “variant of uncertain significance" or VUS.
Numerous genetic variations are identified as “related” to a medical condition, but it is uncertain if they actually lead to disease, said study senior author Joseph C. Wu, M.D., Ph.D., director of the Stanford Cardiovascular Institute and Simon H. Stertzer, M.D. Endowed Professor in the Department of Medicine (Cardiology) and Department of Radiology at the Stanford University School of Medicine in California.
“Random genetic testing will create a lot of stress for a healthy individual who may be getting echocardiograms, MRIs or medications that they may not need,” Wu said. “Results from this study will help improve the interpretation and diagnostic accuracy of gene variants, especially in the era of personalized medicine and precision health. The goal is to optimize the decision making of clinicians in their choices of therapy by providing a much clearer result for the ‘variant of uncertain significance’ carriers.”
Researchers studied genetic variants associated with hypertrophic cardiomyopathy, a condition in which the heart muscle thickens. It is a common cause of sudden cardiac death in young people and young athletes.
They harvested DNA from 54 "healthy" or symptom-free individuals without heart disease, then sequenced their DNA using a custom DNA panel of 135 cardiomyopathy and congenital heart disease genes associated with sudden cardiac death.
The sequence results uncovered 592 unique genetic variants, with 78 percent of genetic variants being classified as “benign,” “likely benign,” or a “variant of uncertain significance.” However, 17 genetic variants were annotated as “likely pathogenic” or disease-causing.
One individual who had multigenerational family members carrying a variation in gene MYL3, which is associated with hypertrophic cardiomyopathy, was chosen in this study.
After collecting the patients’ peripheral blood mononuclear cells, the cells were reprogrammed to induced pluripotent stem cells (iPSCs) and genome edited using the CRISPR/Cas9 gene editing technology to engineer cells with the same genetics (isogenic iPSC lines). Comprehensive analysis was next performed on the engineered cell lines to determine the MYL3 variant could lead to disease.
Traditionally, treating hypertrophic cardiomyopathy depends on whether a patient has symptoms and the severity of those symptoms. People who have "silent" hypertrophic cardiomyopathy without symptoms are not treated. For those with symptoms, physicians may recommend lifestyle changes such as adopting a heart-healthy diet, reducing stress and incorporating exercise while treating underlying illnesses that can make the condition worse. They may also prescribe medications for hypertrophic cardiomyopathy, typically reserving surgery for more severe cases.
“Given the diversity of the human genome – no one of us is identical to another – it is difficult to determine whether a genetic “variant” is meaningful or not. As a result, we risk treating patients with medications or more for a variant that, in the end, is benign,” said Circulation editor, Joseph A. Hill, M.D., Ph.D., chief of cardiology at UT Southwestern Medical Center in Dallas. “This study combined two new powerful technologies, induced pluripotent stem cells and CRISPR-Cas9 gene editing, to model a patient’s heart in a dish and to test whether those heart cells manifested signs of disease. This approach heralds a new era of in vitro disease modeling and drug testing as pivotal elements of precision medicine.”
Co-authors are Ning Ma, Ph.D.; Joe Zhang M.D., Ph.D.; Ilanit Itzhaki, Ph.D.; Sophia Zhang, Haodong Chen, Ph.D.; Francois Haddad, M.D.; Tomoya Kitani, M.D., Ph.D.; Kitchener D. Wilson, M.D., Ph.D.; Lei Tian, Ph.D.; Rajani Shrestha; Haodi Wu, Ph.D.; Chi Keung Lam Ph.D.; and Nazish Sayed, M.D., Ph.D. The authors had no financial disclosures.
This study was funded by the Stanford Frankenstein@200 grant, National Institutes of Health and the American Heart Association Merit Award.
- Available multimedia is on the right column of the release link - https://newsroom.heart.org/news/gene-editing-technology-may-improve-accuracy-of-predicting-individuals-heart-disease-risk?preview=6a8ca9dbdb678e9cc7f315b1fb0ecd01
- After June 18, view the manuscript online.
- Hypertrophic Cardiomyopathy
- AHA Scientific Statement: Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine
- AHA Scientific Statement: Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine
- AHA's Institute for Precision Cardiovascular Medicine
- Follow AHA/ASA news on Twitter @HeartNews
- For updates and new science from the Circulation journal follow @CircAHA
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at www.heart.org/corporatefunding.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
For Media Inquiries and AHA/ASA Spokesperson Perspective: 214-706-1173
Bridgette McNeill: 214-706-1135; email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)